Augmenting generalizability of automated methods with local fine-tuning can help providers diagnosis osteoporosis with these scans.
Identifying patients who have osteoporosis can be easier on abdominal CT scans with automated methods that have improved generalizability.
It is well known that measuring the Hounsfield unit (HU) in the L1 vertebral body (VB) is an opportunistic way to screen patients for osteoporosis. But, the HU thresholds may not generalize well between different groups based on population and imaging protocol differences.
To see whether it is possible to augment opportunistic osteoporosis screening, Steven Rothenberg, M.D., assistant professor of diagnostic radiology at the University of Maryland School of Medicine, compared two deep learning model approaches to an external institution. His team first applied previously established thresholds to automatically extracted L1 HU, and they also trained a locally fine-tuned model using automatically extracted HUs, bone mineral densities (BMD), and demographic variables.
Rothenberg presented the team’s results in a poster during the Society for Imaging Informatics in Medicine (SIIM) 2021 Virtual Annual Meeting.
For more SIIM 2021 coverage, click here.
For the study, the team used a deep learning model that had been trained on images from one institution to automatically segment lumbar VBs on abdominal CTs and to extract trabecular HUs from each body in order to assess the external dataset from their local site.
They gathered 200 consecutive abdominal CTs from their hospital that had undergone DEXA examination within six months over a two-year timeframe. They, first, applied L1 VB HU cut-offs to diagnose potential osteoporosis, and, then, they used age and sex data alongside automatically-extracted L1 and L2 HU and BMD to train both decision tree and random forest models for osteoporosis diagnosis.
Based on their analysis, the locally fine-tuned random forest and decision tree models had average F1 scores of 0.84 and 0.8, respectively. These results outperformed the 0.54 and 0.46 scores achieved by L1 HU thresholds of 80 and 120, respectively. In addition, they team determined the average sensitivity for the fine-tuned models were greater than 80 percent – far outpacing the 40 percent and 57 percent achieved by the two HU thresholds.
Overall, the team said, their results indicate that local models that are fine-tuned on demographic variables and automatically-extracted VB HU and BMD data do result in improved generalization for opportunistic osteoporosis screening.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.